Ribociclib plus endocrine therapy boosts survival of HR+/HER2- breast cancer
Delaying initiation of radiotherapy after starting androgen deprivation therapy (ADT) for localized high-risk prostate cancer is a treatment-sequencing question within radiation oncology and genitourinary oncology, evaluated through comparative survival analysis across defined time-window cohorts. The underlying principle is that treatment-timing flexibility can be assessed via large-cohort observational data comparing long-term survival outcomes across different intervals between initiating systemic therapy and initiating local radiotherapy, informing risk-adapted scheduling decisions.
Ribociclib plus endocrine therapy boosts survival of HR+/HER2- breast cancer
Delaying initiation of radiotherapy after starting androgen deprivation therapy (ADT) for localized high-risk prostate cancer is a treatment-sequencing question within radiation oncology and genitour…